Table 2. Univariate and multivariate analysis of prognostic factors for overall survival in sCRC patients (n = 48).
| Patient tumor features | N. of cases (%) | Median OS (months) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | p-value | Hazard Ratio | 95% CI | p-value | |||
| Tumor size | .001 | NS | ||||||
| ≤5 cm | 32 (67%) | 149 | - | - | ||||
| 5.1–6.9 cm | 4 (8%) | 16 | 6.6 | 2.1–21 | ||||
| >7 cm | 12 (25%) | 73 | 1.5 | 0.6–3.6 | ||||
| CEA serum levels | .005 | NS | ||||||
| ≤7.5 ng/ml | 28 (58%) | 165 | - | - | ||||
| >7.5 ng/ml | 20 (42%) | 41 | 2.82 | 1.3–6 | ||||
| Histopathological grade | .007 | NS | ||||||
| Well-differentiated | 29 (60%) | 165 | - | - | ||||
| Moderately/poorly-differentiated | 19 (40%) | 44 | 2.8 | 1.2–6 | ||||
| Lymph node involvement | <.001 | <.001 | ||||||
| N0 | 33 (69%) | 165 | - | - | ||||
| N ≥ 1 | 15 (31%) | 25 | 7.2 | 3.1–17 | 6.54 | 2.5–17 | ||
| Extranodal metastasis at diagnosis | <.001 | NS | ||||||
| No | 35 (73%) | 165 | - | - | ||||
| Yes | 13 (27%) | 25 | 8.3 | 3.3–21.7 | ||||
| TNM stage at diagnosis | <.001 | NS | ||||||
| I–IIIC | 35 (73%) | 165 | - | - | ||||
| IV | 13 (27%) | 25 | 8.3 | 3.2–21.7 | ||||
| sCRC GEP-classifier | <.001 | <.001 | ||||||
| Non-MTX-like | 28 (58%) | NR | - | - | ||||
| MTX-like | 20 (42%) | 25 | 7.5 | 3.3–17 | 7 | 2.9–17.1 | ||
CI: confidence interval; NR: not reached; NS: no statistically significant differences found (p ≤ .05); CEA: carcinoembryonic antigen.